# Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease

> **NCT02960503** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Vanderbilt University**

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Azithromycin
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02960503
- **Lead sponsor:** Vanderbilt University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2016-09
- **Primary completion:** 2018-10
- **Final completion:** 2018-10
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Key personnel moved to new location. Therefore, we had insufficient resources to initiate the trial.
- **Last updated:** 2018-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02960503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02960503, "Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02960503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*